Antibodies to SOX13 (ICA12) are associated with type 1 diabetes

H. Kasimiotis, S. Fida, M. J. Rowley, I. R. Mackay, P. Z. Zimmet, S. Gleason, D. U. Rabin, M. A. Myers

Research output: Contribution to journalArticleResearchpeer-review

9 Citations (Scopus)


SOX13 is an islet cell autoantigen (ICA12), identified by antibody screening of an islet cDNA library, using sera from patients with Type 1 diabetes. We ascertained the frequency of antibody reactivity to SOX13 and compared it with other Type 1 diabetes autoantibody reactivities. Antibodies were measured by radioimmunoprecipitation (RIP) using 35S labelled SOX13 expressed in rabbit reticulocyte lysate. Sera from 109 subjects with Type 1 diabetes, 29 with Type 2 diabetes, 144 with other autoimmune diseases and from 201 controls were tested for anti-SOX13, and results were compared with the frequency of antibodies to glutamic acid decarboxylase (anti-GAD), islet cell antigen 512 (anti-ICA512) and islet cell cytoplasm (ICA). Anti-SOX13 were detected in 20 (18.3%) of 109 subjects with Type 1 diabetes, and more frequently in adults than in children (29% vs 10%). Anti-SOX13 usually occurred with anti-GAD but rarely with anti-ICA512. Seven sera positive for anti-SOX13 did not react with either GAD, ICA512 or islet cell cytoplasm indicating that anti-SOX13 represented a distinct population of antibodies. Reactivity to SOX13 represents a further autoantibody response in adults with Type 1 diabetes and may provide a useful disease marker in subjects in whom other autoantibody tests are negative.

Original languageEnglish
Pages (from-to)95-101
Number of pages7
Issue number2
Publication statusPublished - 1 Jan 2001


  • Autoantibodies
  • Autoimmunity
  • ICA12
  • SOX13
  • Type 1 diabetes

Cite this